The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms for those who already suffer from conditions like anxiety and depression.
The SlideShare 101 is a quick start guide if you want to walk through the main features that the platform offers. This will keep getting updated as new features are launched.
The SlideShare 101 replaces the earlier "SlideShare Quick Tour".
This document discusses strategies to improve access to drugs for rare diseases in Canada. It proposes establishing Centres of Expertise across the country to provide coordinated rare disease services. It also recommends creating a national rare disease research network and an accelerated drug access pathway. This would involve concurrent regulatory review and managed access programs to provide early access to drugs while collecting additional evidence. The goal is to deliver on the promise of value-based access to rare disease treatments for Canadians.
The document summarizes a webinar on rare diseases held on June 9th, 2023. It discusses the mandate of CORD-RQMO, which is a network of over 100 patient groups that aims to improve the lives of those with rare diseases. It outlines some of the services provided through IRARE, including information sharing and awareness raising. It also discusses challenges with drug access for rare diseases in Canada, including slow reimbursement processes and limited access and treatment for eligible patients. Finally, it announces that the federal government will invest up to $1.5 billion over 3 years in a new Rare Disease Drug Strategy to improve access to drugs and support for patients.
On this webinar, we’ll hear from experts on the issue and invite an open conversation with stakeholders. We need discussion, shared questions and answers and a review of case studies, which is why we are hosting this session.
Panelist:
Neil Palmer, Principal Consultant, WN Palmer & Co. and former PMPRB staff
Michael Dietrich, Executive Director, Policy, Innovative Medicines Canada
Laurene Redding, Global Head, Strategic Pricing (ex-China), BeiGene
Durhane Wong-Rieger, President & CEO, CORD
Moderator: Bill Dempster, CEO, 3Sixty Public Affairs
Rare Disease Drug Access within Rare Disease System
This document discusses challenges with rare disease drug access and proposes frameworks to address barriers. It summarizes an operational description of rare diseases developed by experts that includes a core definition and descriptive framework. The frameworks recognize challenges from a disease's rarity, the need for greater recognition of rare disease burden, and that addressing unmet needs requires coordinated action. The document also outlines health system pathways to treatment access and frameworks for mapping the drug journey and identifying barriers. It proposes three pillars - financing, health services, and governance - for optimal rare disease drug programs.
The SlideShare 101 is a quick start guide if you want to walk through the main features that the platform offers. This will keep getting updated as new features are launched.
The SlideShare 101 replaces the earlier "SlideShare Quick Tour".
This document discusses strategies to improve access to drugs for rare diseases in Canada. It proposes establishing Centres of Expertise across the country to provide coordinated rare disease services. It also recommends creating a national rare disease research network and an accelerated drug access pathway. This would involve concurrent regulatory review and managed access programs to provide early access to drugs while collecting additional evidence. The goal is to deliver on the promise of value-based access to rare disease treatments for Canadians.
The document summarizes a webinar on rare diseases held on June 9th, 2023. It discusses the mandate of CORD-RQMO, which is a network of over 100 patient groups that aims to improve the lives of those with rare diseases. It outlines some of the services provided through IRARE, including information sharing and awareness raising. It also discusses challenges with drug access for rare diseases in Canada, including slow reimbursement processes and limited access and treatment for eligible patients. Finally, it announces that the federal government will invest up to $1.5 billion over 3 years in a new Rare Disease Drug Strategy to improve access to drugs and support for patients.
On this webinar, we’ll hear from experts on the issue and invite an open conversation with stakeholders. We need discussion, shared questions and answers and a review of case studies, which is why we are hosting this session.
Panelist:
Neil Palmer, Principal Consultant, WN Palmer & Co. and former PMPRB staff
Michael Dietrich, Executive Director, Policy, Innovative Medicines Canada
Laurene Redding, Global Head, Strategic Pricing (ex-China), BeiGene
Durhane Wong-Rieger, President & CEO, CORD
Moderator: Bill Dempster, CEO, 3Sixty Public Affairs
Rare Disease Drug Access within Rare Disease System
This document discusses challenges with rare disease drug access and proposes frameworks to address barriers. It summarizes an operational description of rare diseases developed by experts that includes a core definition and descriptive framework. The frameworks recognize challenges from a disease's rarity, the need for greater recognition of rare disease burden, and that addressing unmet needs requires coordinated action. The document also outlines health system pathways to treatment access and frameworks for mapping the drug journey and identifying barriers. It proposes three pillars - financing, health services, and governance - for optimal rare disease drug programs.
1) The document outlines Canada's strategy for rare diseases and rare drug access. It discusses the need for improved coordination between patients, healthcare providers, regulators, insurers, and industry.
2) A key focus is on patient engagement and empowerment throughout the process, from diagnosis to treatment to ongoing care. The roles and advocacy of patient groups have changed over time.
3) The strategy proposes several pillars to guide improvement, including increasing access to rare disease treatments consistently across Canada, optimizing evidence collection to inform decisions, supporting optimal patient outcomes and healthcare sustainability, and strengthening alignment between research and innovation systems and access objectives.
This document summarizes a presentation about creating Canada's rare disease network. It discusses barriers to accessing treatments, the role of physician advocacy, and an approach taken in Manitoba and Saskatchewan to build capacity for diagnosing hereditary metabolic disorders. A key part of this approach is the "OMICS First" strategy of starting with comprehensive DNA testing rather than traditional testing. This aims to improve timelines, reduce hospital stays and tests, and lower costs while maintaining quality of care. The presentation also discusses challenges of pricing for rare disease treatments and the need for real-world evidence to be incorporated into decision making.
CORD Rare Drug Conference: June 8-9, 2022
Registries and Real-World Data
INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty,
Monica Lamoureux, John Adams, Kim Angel
Orion Buske, CEO of Phenotypes, gave a presentation at the CORD Spring Conference in June 2022 about using patient phenotypes to drive genomic diagnostics for rare diseases. He explained that while genome sequencing can diagnose thousands of genetic conditions at once, clinicians need detailed phenotypic information to determine which are relevant to each patient's condition. PhenoTips is a digital platform that uses structured phenotypic data from sources like the Human Phenotype Ontology to help match patients to potential diagnoses, genes, and other related information to support precision medicine. It allows data sharing between hospitals, clinics, and research initiatives to help solve more rare disease cases.
This document summarizes a presentation by Dr. Kym Boycott on clinical genome-wide sequencing. The key points are:
- Genome-wide sequencing (GWS) can diagnose 25-60% of rare genetic diseases, improving patient care and reducing misdiagnoses. However, it requires specialized interpretation and many patients see multiple specialists over 3-6 years before receiving a diagnosis.
- Over 200,000 rare disease patients have been clinically sequenced worldwide. Guidelines developed in Canada recommend GWS for diagnostic evaluation.
- Projects in several Canadian provinces are working to implement clinical GWS, but a national data solution is needed to realize the promise of precision medicine for rare diseases in Canada.
- The proposed
CORD Rare Drug Conference: June 8-9, 2022
Registries and Real-World Data
INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty,
Monica Lamoureux, John Adams, Kim Angel Opportunities and Challenges for Data Management
CORD Rare Drug Conference June 8-9, 2022
Global, International, and National Rare Disease Networks
Rare Disease Research Network and National Children’s Hospital - Marshall
Summar, Rare Disease Institute
CORD Rare Drug Conference: June 8-9, 2022
Global, International, and National Rare Disease Networks
WHO-RDI Global Rare Disease Network - Matt Bolz-Johnson, EURORDIS
CORD Rare Drug Conference: June 8-9, 2022
Global, International, and National Rare Disease Networks
Canadian Network of Rare Disease Centres of Excellence - Paula Robeson, Children’s Healthcare Canada
Bonescanada.org aims to empower healthcare professionals and patients dealing with childhood-onset rare bone disorders through collaboration, a multidisciplinary team of experts, and overcoming challenges like limited resources, integrating research and care, and facilitating technology and regulatory processes. They have enrolled over 400 children in their research program on conditions like Duchenne muscular dystrophy and osteogenesis imperfecta, using centralized imaging to support international clinical trials. Lessons from research also inform their clinical program and advocacy efforts.
Canada lags behind Europe in approving and publicly reimbursing drugs for rare diseases:
- Of 63 drugs approved by EMA from 2015-2020, only 24 completed negotiations for public coverage in Canada.
- Less than half of 41 drugs approved by Health Canada received public reimbursement.
- The time from regulatory approval to reimbursement is typically 1-2 years in most Canadian provinces.
CORD Rare Drug Conference, June 8 - 9, 2022
Opportunities and Challenges for Data Management Real-World Data and Real-World Evidence
• Patient support programs: Sandra Anderson, Innomar Strategies
• AI for Data Management and Enhancement: Aaron Leibtag, Pentavere
• Patient Support and RWE: Laurie Lambert, CADTH
The document describes Khure Health, a company that uses artificial intelligence and natural language processing on electronic medical record data to develop clinical decision support algorithms for over 100 rare and complex diseases, with the goal of helping physicians more quickly and accurately diagnose patients through clinical decision support tools and access to clinical specialists. Khure Health's platform analyzes a patient's full clinical history and test results to identify potential diagnoses and optimized care pathways for high-risk complex patients.
May 19: Leave No One Behind
Panelists
Brad Alyward, Head Market Access & Health Policy, Indivior
Catherine Boivin, Patient Advocate, CORD
Shona Kinley,Director, Federal Policy & Government Affairs, Novartis
Bennett Lee, Head, Value & Access, Sanofi
Joan Paulin, Patient Advocate, PHA Canada
Trevor Richter, Director of Access and Reimbursement, Gilead
Rare Disease Centres of Excellence Webinar May 5, 2022
Christopher McMaster/Etienne Richer, CIHR Institute of Genetics
Craig Campbell, Department of Pediatrics, Western University
Domenica Talarico, European Reference Networks
Matt Bolz-Johnson, WHO-RDI Global Rare Disease Network
Bashundhara Toiletries Logo Guideline 2024khabri85
It outlines the basic identity elements such as symbol, logotype, colors, and typefaces. It provides examples of applying the identity to materials like letterhead, business cards, reports, folders, and websites.
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...DrDevTaneja1
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
More Related Content
More from Canadian Organization for Rare Disorders
1) The document outlines Canada's strategy for rare diseases and rare drug access. It discusses the need for improved coordination between patients, healthcare providers, regulators, insurers, and industry.
2) A key focus is on patient engagement and empowerment throughout the process, from diagnosis to treatment to ongoing care. The roles and advocacy of patient groups have changed over time.
3) The strategy proposes several pillars to guide improvement, including increasing access to rare disease treatments consistently across Canada, optimizing evidence collection to inform decisions, supporting optimal patient outcomes and healthcare sustainability, and strengthening alignment between research and innovation systems and access objectives.
This document summarizes a presentation about creating Canada's rare disease network. It discusses barriers to accessing treatments, the role of physician advocacy, and an approach taken in Manitoba and Saskatchewan to build capacity for diagnosing hereditary metabolic disorders. A key part of this approach is the "OMICS First" strategy of starting with comprehensive DNA testing rather than traditional testing. This aims to improve timelines, reduce hospital stays and tests, and lower costs while maintaining quality of care. The presentation also discusses challenges of pricing for rare disease treatments and the need for real-world evidence to be incorporated into decision making.
CORD Rare Drug Conference: June 8-9, 2022
Registries and Real-World Data
INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty,
Monica Lamoureux, John Adams, Kim Angel
Orion Buske, CEO of Phenotypes, gave a presentation at the CORD Spring Conference in June 2022 about using patient phenotypes to drive genomic diagnostics for rare diseases. He explained that while genome sequencing can diagnose thousands of genetic conditions at once, clinicians need detailed phenotypic information to determine which are relevant to each patient's condition. PhenoTips is a digital platform that uses structured phenotypic data from sources like the Human Phenotype Ontology to help match patients to potential diagnoses, genes, and other related information to support precision medicine. It allows data sharing between hospitals, clinics, and research initiatives to help solve more rare disease cases.
This document summarizes a presentation by Dr. Kym Boycott on clinical genome-wide sequencing. The key points are:
- Genome-wide sequencing (GWS) can diagnose 25-60% of rare genetic diseases, improving patient care and reducing misdiagnoses. However, it requires specialized interpretation and many patients see multiple specialists over 3-6 years before receiving a diagnosis.
- Over 200,000 rare disease patients have been clinically sequenced worldwide. Guidelines developed in Canada recommend GWS for diagnostic evaluation.
- Projects in several Canadian provinces are working to implement clinical GWS, but a national data solution is needed to realize the promise of precision medicine for rare diseases in Canada.
- The proposed
CORD Rare Drug Conference: June 8-9, 2022
Registries and Real-World Data
INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty,
Monica Lamoureux, John Adams, Kim Angel Opportunities and Challenges for Data Management
CORD Rare Drug Conference June 8-9, 2022
Global, International, and National Rare Disease Networks
Rare Disease Research Network and National Children’s Hospital - Marshall
Summar, Rare Disease Institute
CORD Rare Drug Conference: June 8-9, 2022
Global, International, and National Rare Disease Networks
WHO-RDI Global Rare Disease Network - Matt Bolz-Johnson, EURORDIS
CORD Rare Drug Conference: June 8-9, 2022
Global, International, and National Rare Disease Networks
Canadian Network of Rare Disease Centres of Excellence - Paula Robeson, Children’s Healthcare Canada
Bonescanada.org aims to empower healthcare professionals and patients dealing with childhood-onset rare bone disorders through collaboration, a multidisciplinary team of experts, and overcoming challenges like limited resources, integrating research and care, and facilitating technology and regulatory processes. They have enrolled over 400 children in their research program on conditions like Duchenne muscular dystrophy and osteogenesis imperfecta, using centralized imaging to support international clinical trials. Lessons from research also inform their clinical program and advocacy efforts.
Canada lags behind Europe in approving and publicly reimbursing drugs for rare diseases:
- Of 63 drugs approved by EMA from 2015-2020, only 24 completed negotiations for public coverage in Canada.
- Less than half of 41 drugs approved by Health Canada received public reimbursement.
- The time from regulatory approval to reimbursement is typically 1-2 years in most Canadian provinces.
CORD Rare Drug Conference, June 8 - 9, 2022
Opportunities and Challenges for Data Management Real-World Data and Real-World Evidence
• Patient support programs: Sandra Anderson, Innomar Strategies
• AI for Data Management and Enhancement: Aaron Leibtag, Pentavere
• Patient Support and RWE: Laurie Lambert, CADTH
The document describes Khure Health, a company that uses artificial intelligence and natural language processing on electronic medical record data to develop clinical decision support algorithms for over 100 rare and complex diseases, with the goal of helping physicians more quickly and accurately diagnose patients through clinical decision support tools and access to clinical specialists. Khure Health's platform analyzes a patient's full clinical history and test results to identify potential diagnoses and optimized care pathways for high-risk complex patients.
May 19: Leave No One Behind
Panelists
Brad Alyward, Head Market Access & Health Policy, Indivior
Catherine Boivin, Patient Advocate, CORD
Shona Kinley,Director, Federal Policy & Government Affairs, Novartis
Bennett Lee, Head, Value & Access, Sanofi
Joan Paulin, Patient Advocate, PHA Canada
Trevor Richter, Director of Access and Reimbursement, Gilead
Rare Disease Centres of Excellence Webinar May 5, 2022
Christopher McMaster/Etienne Richer, CIHR Institute of Genetics
Craig Campbell, Department of Pediatrics, Western University
Domenica Talarico, European Reference Networks
Matt Bolz-Johnson, WHO-RDI Global Rare Disease Network
Bashundhara Toiletries Logo Guideline 2024khabri85
It outlines the basic identity elements such as symbol, logotype, colors, and typefaces. It provides examples of applying the identity to materials like letterhead, business cards, reports, folders, and websites.
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...DrDevTaneja1
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
Test bank clinical nursing skills a concept based approach 4e pearson educati...rightmanforbloodline
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson education
Cyclothymia Test: Diagnosing, Symptoms, Treatment, and Impact | The Lifescien...The Lifesciences Magazine
The cyclothymia test is a pivotal tool in the diagnostic process. It helps clinicians assess the presence and severity of symptoms associated with cyclothymia.
Emotional and Behavioural Problems in Children - Counselling and Family Thera...PsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Solution manual for managerial accounting 18th edition by ray garrison eric n...rightmanforbloodline
Solution manual for managerial accounting 18th edition by ray garrison eric noreen and peter brewer_compressed
Solution manual for managerial accounting 18th edition by ray garrison eric noreen and peter brewer_compressed
Malayali Kerala Spa in Ajman, one among the top rated massage centre in ajman, welcomes you to experience high quality massage services from massage staffs from all ove rthe world! Being the best spa massage service providers, we take pride in offering traditional massage services of different countries, like
Indian Massage, Kerala Massage, Thai Massage, Pakistani Massage, Russian Massage etc
If you are seeking relaxation, pain relief, or wellness experience, our ajman spa is here for your unique needs and concerns. The services of our experienced therapists, and personalized attention will ensure that each visit will be memorable for you.
Book your appointment today and let us take you to a world of serenity and self-care. Because you deserves the best.
About CentiUP - Introduction and Products.pdfCentiUP
A heightened child formula, with the trio of Nano Calcium, HMO, and DHA mixed in the golden ratio, combined with NANO technology to help nourish the body deeply and comprehensively, helps children increase height, boost brain power, and improve the immune system and overall well-being.
Thanks for the kind introduction.
I am Isabel Jordan, and my perspective today is the parent reviewer on the Rare Disease Foundation Microgrant reviews
I thought long and hard about what I could bring to this Research Forum today.
I am not clinician or a health care provider.
I am not a PhD
I am not a researcher.
So what can I bring to the research review process? How can parents & lay reviewers contribute.
I am a parent to these 2 amazing children. – Zach is 13 years old and Evie is 10.
Zack has an undiagnosed rare disease. And Evie is his typical little sister who spends much time worrying about her big brother.
I am a builder and believer in networks both online and offline.
As myself and as a member of the rare disease foundation.
Online and offline I believe in the collective wisdom of families, patients, caregivers, doctors and allied health professionals. Furthermore, I deeply believe that it is in the intersections of those relationships and communications that the wisdom lies that will bring patient care forward, individually and collectively.
And I am deeply, deeply entrenched in the day to day life of living within a family and community impacted by rare disease. Not just because of my volunteer work with the rare disease foundation, but because of my where my family situation has brought me…
Because my perspective comes not from a professional affiliation or education, but from our family lived experience…
For those of you on the other side of the desk, on the other side of the exam table, please let me tell you pull back the curtain of my experience. My son is 13. After seven or so specialists, many tests, much chronic pain, on again off again, on again disability, a rare tumour, an impressive surgery, and ICU stay, we still have no answers. Personally, our medical journey is still one of gathering data. Communicating with our healthcare providers and cobbling together management strategies that can maximize our son’s quality of life. Some days are bad. This year, he’s missed 70% of his classes because of pain, nausea & fatigue. This for a kid who’s already decided he’s going to have a PhD in Marine Biology and study the deep ocean. Personally, we often feel completely powerless and buffeted by forces we can’t understand and have no control over. But this is our reality and the reality shared by most in the rare disease community.
But what does this have to do with reviewing research grants?
What colour is this dress?
No matter how many times I saw this come across my facebook or twitter feed last week I could not see this dress as the blue and black pictured on the right. In fact, even though I recognize that, logically, I know people aren’t lying (because I trust them) when they tell me they see the dress that way, I can’t actually personally conceive of it that way.
What is amazing to me is how this, apparently frivolous internet meme went viral, pointing out how not only we can see things differently, but that we may not even REALIZE that others are seeing the same thing in a completely different way. It was such a beautifully concrete way to show this. I used it as a great example for my kids, but I think all of us can use this object lesson. None of us are seeing it ‘wrong’. None of us have the negative or positive perspective. We are all valid. We just need everyone’s perspective to see a full representation of reality.
I see rare disease research the same way. It is #thedress. (I hashtagged that in my mind, by the way). Traditional ways of reviewing grant proposals have only had one perspective, that of scientific reviewers. That perspective is not wrong. It is completely valid, for what it represents,but it is not the full picture. In order to see the full picture we need to bring in a diversity of voices to fund the research that affects the community it most effects.
Here’s an aside, most people see the dress as white and gold, however, in reality the dress is blue and black.
Bringing in the patient and family community has real benefit to the research funding process and I’ve seen this through participating myself for the past several years.
Sometimes specific projects are funded that the scientific community just doesn’t realize are a priority to the rare disease community and turn out to have a large impact on care. And speaking of that – one of the real benefits, IMO for the RDF Microgrant program is maintaining the focus on the care-focused nature of our program – that is our priority and that is something the lay reviewers tend to keep a laser focus on.
Less concretely, but just as important it forges and maintains a connections b/w the pt and family community and the research community that can keep them engaged in studies and even engage them in fundraising that can fuel further research.
Not just about the research. Reviewing can be an intense process. It’s not often but when it happens it can be time consuming. Why would the lay reviewer participate?
Taking a look at the life of a person/family with RD..
Juggling – medications, hospitalization, schedulint OT, PT, SLP and other appointments, food restrictions, specialized diets, special school plans IEPs, scheduling OT, PT, SLP and that’s just for the affected family member. We also have our jobs, and the rest of our household to manage.
Life like this can leave me feeling overwhelmed, worried, confused and frankly, just plain old tired.
Why on earth would I take on anything else that’s optional?
I can only speak for myself, well, myself and some of the other reviewers I spoke to!
There is one main reason..
As I indicated, the rare disease life is one of frustration with few answers. Many of us don’t hold out a lot of hope that we’ll get definitive answers. Wait, that sounds too… harsh. We do have hope, but we don’t have.. expectation. For me this process has been somewhat liberating. Twice a year, for the past 6 years I have been astounded by what researchers and doctors and students and nurses and genetic counsellors have come up with for ideas on how to concretely help the rare disease community. In the vast majority of cases, most of these grant proposals will have zero impact on my life or my family’s life. But they do have the potential to impact a family JUST LIKE MINE. Another parent who lurches from appointment to appointment wondering what will come next, and maybe, one of these little studies will make their journey just that little bit easier. Participating in this process, effects a change in my community that I can be a part of.
Listen to that. Feel that. I, as a parent, can be a part of creating the greater good for research into the rare disease community. I can help set the direction to create care-focussed research. I can represent the priorities that are important to us, the parents, the patients. I am doing that. I can’t find a diagnosis for my son, or treatment, or even if he can make it to school tomorrow. But I can do that
There’s something else going on here as well. Our vision at the Rare Disease Foundation, from the beginning has been that the patient and family voice is on an equal and collaborative level with that of the clinician and the researcher – that together these different kinds of knowledge are what will drive research forward. Where this is true on patient level, it is also true on a more macro, research level as well.
I was so intimidated at the beginning that I didn’t have the specialized medical/scientific knowledge to rank the reviews. This is a feeling shared by my other parent reviewers. Those I spoke to ALL echoed this sentiment. But here’s what I understand now. That is ok. We are bringing something else to the table. We see the dress as blue and black. The scientific researchers can only see it as white and gold and we are there to make sure that blue and black perspective is shared. In fact, if we weren’t there, they wouldn’t even know that anyone saw the dress as blue and black. And the quality, depth and breadth of research that was funded would be poorer for it.
Moving forward, how to we supercharge our parent reviewers? How do we make this work even better?
I think we need more. I think that having more perspectives helps us make better decisions. I am not the rare disease community I am Isabel Jordan, @seastarbatita and I am both bound and lifted by my experiences. Having more critical thinkers who understand our model and our goals will make the process more robust. But, it is time consuming when we go through it, and as a rare disease community, there are time demands and pressures that are not ours to control.
I had a steep learning curve to getting to trust my instincts, to figuring out that I wasn’t meant to be a scientific reviewer. Of course, the total nerd in me wants to understand all the science and our lay reviewers need to have enough understanding to be able to read through the summaries, but I needed to know where it was ok for my understanding to stop. I still somewhat struggle with that.
I believe in this concept – that together we make better decisions. Together we have a complete picture of what constitutes better care for the rare disease community. My perspective isn’t the only one parent perspective, I’m only a small piece of the picture but I do feel confident that more informed voices will mean a better decision.